| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q3'26 | September 9, 2026 | - | - | 2 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q3'26 | Delivered | June 4: materially more active repurchases going forward Q3 purchases $339.1 million versus approximately $13 million in Q2 |
| Q3'26 | Delivered | June 4: strategic-review update by next earnings call Review completed; Surgical retained |
| Q3'26 | Pending | June 4: Asia Pacific to match market growth by Q4 Q3 organic decline of 5%; near-term challenges persist |
| Q3'26 | Pending | June 4: $2.2 billion cumulative FY2026-FY2028 FCF, including litigation payouts Objective reaffirmed |
| Q3'26 | Pending | June 4: approximately $650 million FY2026 FCF, excluding litigation payouts $528.1 million YTD FCF plus approximately $170 million Q4 before excluded payments |
| Q3'26 | Pending | June 4: FY2026 revenue $4.28-$4.32 billion; adjusted EPS $4.58-$4.66 Both ranges reduced |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.